Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome

Brain

Volumn 132, Issue 9, 2009, Pages 2403-2412

  Connor, James R ^a   Wang, Xin Sheng ^a   Allen, Richard P ^b   Beard, John L ^c   Wiesinger, Jason A ^c   Felt, Barbara T ^d   Earley, Christopher J ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Basal ganglia; Iron deficiency; Movement disorders; PC12 cells; Sleep disorders

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; AUTOPSY; BASAL GANGLION; BRAIN LEVEL; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IRON CHELATION; IRON DEFICIENCY; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; RESTLESS LEGS SYNDROME; SENSORIMOTOR NEUROPATHY; SLEEP DISORDER; SUBSTANTIA NIGRA;

EID: 71549117331     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp125     Document Type: Article

References (41)

1. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004; 5: 385-391.
2. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56: 263-265.
3. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2008; 10: 123-128.
4. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000; 1: 11-19.
5. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
6. Beard J. Iron deficiency alters brain development and functioning. J Nutr 2003; 133 (5 Suppl. 1): 1468S-72S.
7. Beard JL, Chen Q, Connor J, Jones BC. Altered monamine metabolism in caudate-putamen of iron-deficient rats. Pharmacol Biochem Behav 1994; 48: 621-624.
8. Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr 2003; 2: 41-58.
9. Beard J, Erikson KM, Jones BC. Neonatal iron deficiency results in irreversible changes in dopamine function in rats. J Nutr 2003; 133: 1174-1179.
10. Cervenka S, Palhagen SE, Comley RA, Panagiotidis Z, Cselenyi JC, Matthews RY, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006; 129: 2017-2028.
11. Clardy SL, Wang X, Boyer PJ, Earley C, Allen R, Connor J. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci 2006; 247: 173-179. (Pubitemid 44339542)
12. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61: 304-309.
13. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004; 62: 1563-1567.
14. Dixon WJ. Analysis of extreme values. Ann Math Stat 1951; 21: 488-506.
15. Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003; 348: 2103-2109.
16. Earley C, Allen RP, Connor JR, Ferrucci L, Troncoso J. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med (in press).
17. Earley CJ, Barker PB, Horská A, Allen RP. MRI-determined regional brain iron concentrations in early and late-onset restless legs syndrome. Sleep Med 2006a; 7: 458-461.
18. Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 2005; 28: 1069-1075.
19. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54: 1698-1700.
20. Earley CJ, Heckler D, Horská A, Barker PB, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004; 5: 231-235.
21. Earley CJ, Hyland K, Allen RP. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov Disord 2001; 16: 144-149.
22. Earley CJ, Hyland K, Allen RP. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006b; 7: 263-268.
23. Eisensehr I, Wetter TC, Linke R, Noachtar S, Lindeiner Hv, Gildehaus FJ, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307-1309.
24. Erikson KM, Jones BC, Beard JL. Iron deficiency alters dopamine transporter functioning in rat striatum. J Nutr 2000; 130: 2831-2837.
25. Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 2001; 69: 409-418.
26. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424-2428.
27. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27: 560-583.
28. Jones BC, Wheeler DS, Beard JL, Grigson PS. Iron deficiency in rats decreases acquisition of and suppresses responding for cocaine. Pharmacol Biochem Behav 2002; 73: 813-819.
29. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre-and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249: 164-170.
30. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 2005; 14: 43-47.
31. Mrowka M, Jobges M, Berding G, Schimke N, Shing M, Odin P. Computerized movement analysis and beta-CIT-SPECT in patients with restless legs syndrome. J Neural Transm 2005; 112: 693-701.
32. Nelson C, Erikson K, Pinero DJ, Beard JL. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 1997; 127: 2282-2288.
33. Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: absence of specific tau-and alpha-synuclein pathology. Mov Disord 2004; 19: 695-699.
34. Schmidauer C, Sojer M, Seppi K, Stockner H, Högl B, Biedermann B, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005; 58: 630-634.
35. Stiasny-Kolster K, Moller JC, Zschocke J, Bandmann O, Cassel W, Oertel WH, et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord 2004; 19: 192-196.
36. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, Antonini A, Dhawan V, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999; 14: 141-145.
37. Tribl GG, Asenbaum S, Klosch G, Mayer K, Bonelli RM, Auff E, et al. Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome (letter to editor). Neurology 2002; 59: 649-650.
38. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932-937.
39. Wang X, Wiesinger J, Beard J, Felt B, Menzies S, Earley C, et al. Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. J Neurol Sci 2004; 220: 59-66. (Pubitemid 38622099)
40. Winkelmann J, Schadrack J, Wetter TC, Zieglgansberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med 2001; 2: 57-61.
41. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. J Neural Transm 2001; 108: 925-941